

*This reprint contains data from a Genentech-sponsored phase III clinical trial that led to the approval of Genentech's product Cathflo<sup>®</sup> Activase<sup>®</sup> (alteplase). The FDA has approved Cathflo<sup>®</sup> Activase<sup>®</sup> (alteplase) for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.*

*This reprint contains information that is not contained in the approved product labeling, including history of catheter thrombolysis; rationale of the COOL-1 trial; additional information on materials, methods, and patients of the COOL-1 trial; and limitations of the COOL-1 trial.*

## **Important Safety Information for Cathflo<sup>®</sup> Activase<sup>®</sup> (alteplase)**

### **Contraindications**

Cathflo Activase should not be administered to patients with known hypersensitivity to alteplase or any component of the formulation.

### **Precautions**

#### ***General***

Certain causes of catheter dysfunction should be considered before treatment with Cathflo Activase (e.g. catheter malposition, mechanical failure, constriction by a suture and lipid deposits or drug precipitates within the catheter lumen). These types of conditions should be considered before treatment with Cathflo Activase.

Excessive pressure should be avoided when Cathflo Activase is instilled into the catheter. Such force could cause rupture of the catheter or expulsion of the clot into the circulation.

#### ***Bleeding***

The most frequent adverse reaction associated with all thrombolytics in all approved indications is bleeding. Cathflo Activase has not been studied in patients known to be at risk for bleeding events that may be associated with the use of thrombolytics. Caution should be exercised with patients who have any condition for which bleeding constitutes a significant hazard.

Should serious bleeding in a critical location (e.g., intracranial, gastrointestinal, retroperitoneal, pericardial) occur, treatment with Cathflo Activase should be stopped and the drug should be withdrawn from the catheter.

#### ***Infections***

Cathflo Activase should be used with caution in the presence of known or suspected infection in the catheter. Using Cathflo Activase in patients with infected catheters may release a localized infection into the systemic circulation. As with all catheterization procedures, care should be used to maintain aseptic technique.

#### ***Hypersensitivity***

Hypersensitivity, including urticaria, angioedema and anaphylaxis, has been reported in association with use of Cathflo Activase. Monitor patients treated with Cathflo Activase for signs of hypersensitivity and treat appropriately if necessary.

#### ***Drug Interactions and Drug/Laboratory Test Interactions***

The interaction of Cathflo Activase with other drugs has not been formally studied. Concomitant use of drugs affecting coagulation and/or platelet function has not been studied.

Potential interactions between Cathflo Activase and laboratory tests have not been studied.

***Carcinogenesis, Mutagenesis, Impairment of Fertility***

Long-term studies in animals have not been performed to evaluate the carcinogenic potential or the effect on fertility.

***Pregnancy***

There are no adequate and well-controlled studies in pregnant women. Cathflo Activase should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Adverse Reactions**

In clinical trials, the most serious adverse events reported after treatment were sepsis, gastrointestinal bleeding, and venous thrombosis.

You may report side effects to the FDA at (800) FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). You may also report side effects to Genentech at (888) 835-2555.

**Please see accompanying full Prescribing Information for additional important safety information.**

# Recombinant Tissue Plasminogen Activator (Alteplase) for Restoration of Flow in Occluded Central Venous Access Devices: A Double-Blind Placebo-Controlled Trial—The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Efficacy Trial

Donald Ponec, MD, David Irwin, MD, William D. Haire, MD, Patricia A. Hill, MPH,<sup>1</sup> Xin Li, PhD,<sup>1</sup> and Edward R. McCluskey, MD, PhD,<sup>1</sup> for the COOL Investigators

**PURPOSE:** Central venous access devices (CVADs) are a mainstay of current medical therapy but often become occluded by thrombus. Tissue plasminogen activator (alteplase), at a dose of 2 mg per 2 mL, has been shown to be effective in restoring flow to catheters proven by radiographic contrast injection to be occluded by thrombus. The purpose of this double-blind placebo-controlled multicenter trial was to determine the efficacy of alteplase in occluded catheters without earlier contrast injections or radiographic examinations.

**MATERIALS AND METHODS:** Patients were eligible for inclusion if blood could not be withdrawn from their catheter after a period of normal function of at least 48 hours. Single or multiple catheters, peripherally inserted central catheters, catheters with valves, and implanted ports were eligible; catheters used for hemodialysis were not included. Patients were randomly assigned to one of two groups. In one group, patients received a first dose of 2 mg alteplase followed, if needed, by a second dose of 2 mg alteplase and a third dose of placebo. The other group received placebo first followed by one 2-mg dose of alteplase and then a second, if needed. Each dose was allowed to dwell for 2 hours and ability to withdraw blood from the catheter was reassessed. The endpoint was restoration of the ability to withdraw and infuse through the catheter. One hundred forty-nine patients were randomized: 74 received placebo first, 75 received alteplase first.

**RESULTS:** After the first 2-hour treatment, function was restored to 74% in the alteplase arm and 17% in the placebo arm ( $P < .0001$  compared to placebo). After one or two treatments, function was restored in 90% of patients. There were no serious study-drug-related adverse events, no intracranial hemorrhage, no major hemorrhage, and no embolic events.

**CONCLUSION:** Infusion of alteplase appeared to be safe and effective in restoring flow to occluded catheters without need for pretreatment radiographic evaluation.

**Index terms:** Central venous access • Thrombolysis • Tissue-type plasminogen activator • Urokinase

J Vasc Interv Radiol 2001; 12:951-955

**Abbreviation:** CVAD = central venous access device

CENTRAL venous access devices (CVADs) have become increasingly integral to modern medical therapy,

and are used for infusion of chemotherapy, blood products, pain medication, nutritional support, pressors, and

other treatments requiring central venous access. Unfortunately, these catheters become occluded as a result of thrombosis at a rate that has been estimated at 25% per year (1). Catheter thrombosis is quickly followed by clinical thrombosis (catheter-related venous thrombosis or obstruction) in a large number of patients (2).

Treatment of occluded CVADs had been performed with use of urokinase (3,4). Since the withdrawal of urokinase from the market, other treatment options have become necessary. Re-

From the Division of Radiology (D.P.), Tri-City Medical Center, Oceanside; Departments of Medicine and Oncology/Hematology (D.I.), Alta Bates Hospital, Oakland, California; Division of Oncology and Hematology (W.D.H.), Nebraska Medical Center, Omaha, Nebraska; and Cardiovascular Clinical Unit (P.A.H., X.L., E.R.M.), Genentech, Inc., South San Francisco, California. The COOL Investigators are listed at the end of this article. Received December 19, 2000; revision requested January 16, 2001;

final revision received April 10; accepted April 13. Supported by Genentech, Inc., South San Francisco, CA. **Address correspondence to** E.R.M., Genentech, Inc., 1 DNA Way, M/S 59, South San Francisco, CA 94080; E-mail: tmc@gene.com

<sup>1</sup> These authors have disclosed the existence of a potential conflict of interest.

combinant tissue plasminogen activator (alteplase) has previously been shown to be very effective in restoring flow to dysfunctional catheters that were proven by radiographic contrast injection to be occluded by thrombus (5). However, almost 40% of dysfunctional catheters are not occluded by thrombus (6); rather, they are obstructed by mechanical problems such as migration and malposition of the intravascular segment or kinking of the subcutaneous segment of the catheter. Because clinical presentation is not specific for the cause of obstruction, radiographic contrast material injection is believed necessary to determine the cause of obstruction and the type of therapy necessary (thrombolytic or mechanical repositioning) (6). Unfortunately, contrast injection studies are often not readily available in clinical practice. Consequently, thrombolytic therapy is often administered empirically to dysfunctional catheters. Consequently, we evaluated the ability of alteplase to restore both infusion and withdrawal function in dysfunctional catheters without earlier radiographic contrast material injection.

## MATERIALS AND METHODS

### Trial Design

This trial was a multicenter, double-blind, placebo-controlled comparison of the rates of restoration of catheter function after treatment for 2 hours with either alteplase (2 mg in 2 mL) or placebo (patients weighing between 10 and 30 kg were given a dose equal to 110% of the internal catheter volume). The secondary goal of the study was to determine the rate of catheter function restoration after one or two treatments with alteplase. Safety endpoints of the study included the rates of study-drug-related intracranial hemorrhages, major hemorrhage, embolic events, and all drug-related serious adverse events.

### Patient Population

Patients were eligible if they were clinically stable and had a dysfunctional indwelling long-term CVAD (peripherally inserted central catheters, catheters with valves, and implanted ports were allowed; catheters used for hemodialysis were not).

Withdrawal dysfunction was defined as the inability to withdraw 3 mL of blood. Patients were excluded if it was not possible to infuse fluids at the volume necessary to infuse study drug into the CVAD, if the CVAD had been inserted less than 48 hours before randomization, or if the occlusion had been discovered more than 24 hours before randomization. Also excluded were patients younger than 2 years of age, who weighed less than 10 kg, who had catheters with any evidence of mechanical or nonthrombotic occlusion, or who had received any fibrinolytic agent within 24 hours of randomization. Subjects who, in the opinion of the investigator, were at high risk for bleeding events or embolic complications, or had a known condition for which bleeding constitutes a significant hazard, were also excluded at the discretion of the individual investigators.

Baseline studies consisted of a medical history, physical examination, and CVAD history, including the date of CVAD insertion and the date the CVAD was last known to function (withdrawal and infusion function). An assessment of CVAD function was performed and recorded at baseline. In subjects with multiple-lumen catheters, only one lumen of the catheter (chosen at the discretion of the investigator at the site) was used throughout the study for assessments of function. Withdrawal function was determined by the following method: An empty 10-mL syringe was attached to the catheter, forming an airtight seal. The syringe plunger was pulled back to the 5-mL mark to attempt to withdraw blood. The CVAD was considered to have withdrawal function if at least 3 mL of fluid (blood and any previously infused fluids) filled the syringe. Infusion function was determined by the following method: A 10-mL syringe with 5 mL normal saline solution was attached to the catheter to gently infuse the saline solution. The CVAD was considered to have infusion function if the entire contents of the syringe could be infused without significant resistance.

### Baseline Characteristics

A total of 150 subjects were enrolled in the study (149 were randomized; one was treated without ran-

domization); 74 in the placebo-first group and 75 in the alteplase-first group. One subject was treated (with alteplase first) but not formally randomized and was therefore not included in the intent-to-treat analysis but is included in the "as-treated" analysis. There were 10 patients randomized but not treated (four in placebo first and six with alteplase first). The catheter types randomized in the trial included 19 single-lumen catheters, 72 double-lumen catheters, 12 triple-lumen catheters, and 46 ports. A total of 26 sites enrolled patients in the trial (17 enrolled 1–4 patients, six enrolled 5–10, one enrolled 13, one enrolled 23, and one enrolled 25). Enrollment occurred from November 1999 through May 2000 with the last patient undergoing follow-up in June 2000. Baseline and demographic data are displayed in **Table 1**.

### Study Procedure

Subjects were randomly assigned by an interactive voice randomization service to one of two groups. Each group had one opportunity to be treated with placebo and two opportunities to be treated with study drug (**Table 2**). In one arm, the first study drug vial contained placebo and the second and third vials contained active alteplase. In the other arm, the first and second study drug vials contained active alteplase and the third contained placebo.

After the first vial of study drug was instilled and allowed to dwell for 120 minutes, function was reassessed to determine if both withdrawal and infusion function were present. If function was successfully restored, the patient exited the study. Patients who did not have successful restoration of function were then treated by instillation of the second vial of study drug that was again allowed to dwell for 120 minutes. Function was again assessed at the end of the second 120-minute period. Patients who did not have successful restoration of function after the second treatment were then treated by instillation of the third vial of study drug that was again allowed to dwell for 120 minutes. Function was finally assessed at the end of the third 120-minute period.

All adverse events that met "good clinical practice" criteria for "serious"

**Table 1**  
Selected Demographic and Baseline Characteristics of the Intent-to-treat Population

Characteristic	PAA (n = 74)	AAP (n = 75)
Sex		
Female	41 (55.4%)	41 (54.7%)
Male	33 (44.6%)	34 (45.3%)
Race		
White	51 (68.9%)	57 (76.0%)
Black	16 (21.6%)	8 (10.7%)
Asian/Pacific Islander	2 (2.7%)	6 (8.0%)
Hispanic	5 (6.8%)	3 (4.0%)
Other	0	1 (1.3%)
Age (y)*	49.6 (19)	50.5 (19)
Weight (kg)*	77.4 (27)	75.0 (20)
CVAD type		
Single	9 (12.2%)	10 (13.3%)
Double	36 (48.6%)	36 (48.0%)
Triple	5 (6.8%)	7 (9.3%)
Port	24 (32.4)	22 (29.3%)
Time from catheter insertion to treatment (d)†	35 (2–977)	39 (2–1678)
Time from last known function to treatment (d)†	1 (0–317)	3 (0–70)

Note.—Patient characteristics were not significantly different between groups. PAA = placebo, then two alteplase doses; AAP = two alteplase doses, then placebo (see Table 2).

\* Values are provided as mean (SD).

† Values are provided as median (range).

**Table 2**  
Specifications of Treatment Arms

Treatment Arm	Vial 1	Vial 2	Vial 3
PAA	Placebo (2 mL)	Alteplase (2 mg/2 mL)	Alteplase (2 mg/2 mL)
AAP	Alteplase (2 mg/2 mL)	Alteplase (2 mg/2 mL)	Placebo (2 mL)

Note.—P = placebo; A = alteplase.

were collected during the study period (which was defined as the time from the first treatment with study drug until successful restoration of catheter function or the final assessment after treatment with three vials of study drug). Additionally, all deaths and serious adverse events that were reported by the investigators as long as 30 days after the treatment with study drug were recorded.

The trial was conducted from November 1999 to June 2000 in 36 hospitals (see list of participants at the end of this article). The study was reviewed by the appropriate institutional review boards and was conducted in accordance with the Helsinki Declaration of 1975 (revised 1983).

### Statistical Analysis

The primary endpoint of the study was the difference in rates of restoration of function in the alteplase-treated group compared with the placebo-treated group after 120 minutes. Cumulative rates of successful restoration of function were also determined after each of the treatment assessments. Primary analysis was by intent to treat regardless of early withdrawal or compliance. Analysis by actual treatment was also performed. Statistical analysis was performed with use of SAS statistical software (SAS, Cary, NC). Statistical comparisons of proportions were performed with use of the Fisher exact test. Exact confidence intervals were calculated with use of binomial

distribution. Confidence intervals were also calculated with use of the binomial distribution. All statistical tests were two-sided and conducted at the 0.05 level of significance.


## RESULTS

### Efficacy

The primary endpoint of the study was the difference in rates of restoration of function in the alteplase-treated group compared with the placebo-treated group after 120 minutes in the intent-to-treat population. After the first 120-minute period, successful restoration of function was demonstrated in 73.9% (51 of 69) of alteplase-treated patients compared with only 17.1% (12 of 70) of placebo-treated patients. The difference in these rates was 56.8% (95% CI: 41.2%–70.8%), which was highly significant ( $P < .0001$ ).

The cumulative rates of restoration of function are shown in the Figure. Successful restoration of function was achieved in 77.1% (54 of 70) of patients who received placebo as the first treatment and alteplase as the second treatment (in patients who did not have restoration of function after the first treatment). Successful restoration of function was achieved in 89.9% (62 of 69) of patients who received alteplase as the first treatment and alteplase as the second treatment (in those patients who did not have restoration of function after the first treatment). After treatment with either alteplase then placebo or placebo then alteplase, the rate of restoration of function was 89.9% (62 of 69). Similar results were achieved in the as-treated population when comparing alteplase against placebo after the first bolus.

Of the 150 patients enrolled in the trial, only five had a weight between 10 and 30 kg. Based on the dosing requirement of 110% of the internal catheter volume, all received a lower dose than the other patients in the trial (dose received: 1.30, 0.80, 0.88, 0.88, and 0.90 mL). Of the five patients, three received placebo first and two received alteplase first. None of the three receiving placebo had catheter function restored, and one of the two who received alteplase had clearance after first dose.



**Figure.** This graph shows the percentage of patients in whom normal catheter function was restored after a single 2-hour treatment with either placebo (P) or active drug (A) after treatment with placebo followed by active drug (PA), two active treatments (AA), placebo followed by active drug twice (PAA), or active drug twice followed by placebo (AAP).

### Safety

In the as-treated population of 140 patients, there were no intracranial hemorrhages, no major hemorrhages, no embolic events, no drug-related serious adverse events, and no drug-related deaths during the study or 30-day follow-up. During the study, only one patient died (day 29 after study drug, from complications of bone marrow transplantation). No patient withdrew from the study because of an adverse event.

### DISCUSSION

To our knowledge, this is the first double-blind, placebo-controlled assessment of the efficacy of alteplase in restoring function to unselected dysfunctional central catheters. Previous studies have been unblinded and/or selected catheters for enrollment that had been demonstrated by radiographic contrast material injection to be occluded by thrombus (5,7). The study demonstrated that alteplase, at a dose of 2 mg in 2 mL, is highly effective and appears safe for empiric use in restoring catheter flow without the requirement that thrombotic obstruction be documented radiographically. All types of central catheters were studied, including single-, double-, and triple-lumen, ports, Groshong catheters, Hickman catheters, apheresis catheters, and peripherally inserted central catheters.

The findings of this study are consistent with the initial report of the use of alteplase for clearing thrombosed catheters by Atkinson et al (7). The efficacy in

the current trial is similar to that reported by Haire et al (5) in the 1994 comparison of the same treatment regimen and dose of alteplase (2 mg in 2 mL for 2 h) with urokinase used at twice its recommended dose. The study by Haire et al (5) reported that alteplase was statistically superior to urokinase and restored function to 89% of CVADs with angiographically proven thromboses. In the current study, angiograms or chest radiographs were not required for study participation. Patients could be selected based only on clinical assessment of the cause of catheter dysfunction. Therefore, we were unable to determine the position, type of occlusion (mural thrombus, fibrin sheath, or intraluminal occlusion), extent of occlusion, or cause of catheter malfunction. Based on our broader inclusion algorithm, we expected to observe a slightly lower efficacy rate after one or two doses of alteplase, presuming that as many as 40% of the dysfunctional catheters would be occluded by mechanical problems rather than thrombosis, as had been previously described (6). The fact that the current study observed similar or higher efficacy rates (90% after one or two doses) suggests that the rate of nonthrombotic obstruction in general clinical practice may be significantly lower than that reported from a single institution. This may be a result of statistical variation, differences in study populations, or varying clinical acumen of the investigators in excluding catheters with mechanical or nonthrombotic occlusions. However, the current study is likely to be representative of current clinical practices whereby patients with catheter dysfunction are often treated empiri-

cally and undergo angiographic evaluation only after initial treatment failures.

The dose of alteplase used in the study was chosen based on the study results of Haire et al (5). No information was collected on higher or lower doses. A number of nonrandomized studies have reported comparable efficacy rates at different (8) and similar (9) doses; however, it is unclear whether other doses would have similar efficacy if studied in a placebo-controlled double-blind study such as this.

The dwell time of 2 hours was also chosen based on the study results of Haire et al (5). The current study did not address shorter dwell times or the relationship of dose and dwell time. Although alteplase is the most rapidly acting thrombolytic drug currently or previously approved for noncardiac uses, time is needed for activation of plasminogen to plasmin and subsequent cleavage of clot-bound fibrin for successful thrombolysis to take place. Other studies (9,10) have reported successful restoration of function after shorter dwell times.

Because many catheters are flushed and maintained with heparinized saline and because alteplase mixing instructions recommend against mixing alteplase with heparin or heparinized saline solution, the question arises whether alteplase at this dose should be used in catheters that may retain residual heparin. The current study did not exclude patients based on previous heparin use, nor did it collect specific information on the flush solutions used. Based on reports of the current use of heparinized flush solutions, it is likely that the current study did include a large number of patients in whom heparin was previously used in their occluded lines. The safety and efficacy profile of the current study suggest that any effect of heparin is unlikely to be clinically important.

The fibrin binding and specificity of alteplase may be responsible for the high rates of efficacy demonstrated in this trial. Unlike with thrombolytic agents such as urokinase, with their lower or nonexistent fibrin binding, which may require prolonged constant infusions or administration of high, systematically thrombolytic doses, a brief instillation of alteplase is all that is necessary to achieve the high rates of patency shown in the current trial. By binding to fibrin and locally activating

plasminogen in the clot, systemic thrombolysis can be avoided. Additionally, because alteplase is not easily washed off clots, unlike non-fibrin-binding thrombolytic drugs, it is likely able to maintain a local effect and thereby require a lower (safer) total dose for successful restoration of catheter function.

The current study did not include catheters that were used for hemodialysis. However, catheters of similar type (tunneled 14-F apheresis catheters) were included in the trial and showed efficacy rates similar to those seen in the overall study. Although numerous reports suggest that alteplase may be safe and effective for restoration of function to catheters used in hemodialysis (11–14), no direct measure was made in the current study.

The safety of alteplase in the current study was encouraging. Although the doses of alteplase used in the current study are between only 2%–4% (2–4 mg) of the usual dose for the treatment of acute myocardial infarction, case studies are unclear as to whether there is a dose of alteplase below which there are no safety issues. Because of the limited number of subjects in the current study, only limited safety conclusions can be drawn. More detailed safety conclusions await the results of the ongoing COOL 2 safety trial.

The current study has several limitations. Because angiograms were not performed, no conclusions can be reached as to the efficacy of restoration of flow based on the cause of catheter malfunction. Additionally, catheters that had been occluded for less than 48 hours were not studied in the current study because they are more likely to be occluded as a result of mechanical problems. Finally, the safety of any thrombolytic therapy cannot be established with the limited number of patients treated in the current study; therefore, an additional study establishing the safety of 1,000 patients treated with 2 mg alteplase was conducted in parallel with this study and will be reported elsewhere.

In summary, this study has shown a profound benefit of alteplase (at a dose of 2 mg in 2 mL) compared to placebo for the restoration of flow to dysfunctional CVADs. This effect was seen in a clinically selected population of patients and did not require angiographic assessment of catheters. The

treatment was well tolerated and no adverse safety events were reported. Therefore, alteplase appears to be safe and effective for restoration of flow to dysfunctional CVADs.

**Acknowledgment:** the participants in the COOL Efficacy Trial were: Jeffrey W. Andrey, MD, Scripps Clinic, La Jolla, CA; John F. Angle, MD, Department of Radiology, University of Virginia Health System, Charlottesville, VA; Joseph M. Carrucci, MD, J.T. Mather Memorial Hospital, Port Jefferson, NY; Carlos M. de Castro III, MD, Duke University Medical Center, Morris Cancer Clinic, Durham, North Carolina; George A. Fisher, Jr, MD, PhD, Departments of Medicine and Oncology, Stanford University Hospital, Palo Alto, California; Paul S. Gaynon, MD, Children's Hospital Los Angeles, Los Angeles, California; Maria de Lourdes A.R. Gomes, MD, Department of Radiology, University of Minnesota Academic Health Center, Minneapolis, Minnesota; William D. Haire, MD, University of Nebraska Medical Center, Omaha, Nebraska; Bruce P. Himelstein, MD, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; David H. Irwin, MD, Alta Bates Comprehensive Cancer Center, Berkeley, California; Jan Jansen, MD, PhD, Indiana Blood and Marrow Transplantation, Indianapolis, Indiana; Sophie M. Lanzkron, Texas Transplant Institute at Southwest Texas Methodist Hospital, San Antonio, Texas; Jane L. Liesveld, MD, University of Rochester Medical Center, Rochester, New York; Steven P. Lipman, MD, Englewood Hospital and Medical Center, Englewood, New Jersey; John Lister, MD, Division of Hematology/Oncology, Western Pennsylvania Hospital, Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania; Paul F. Mansfield, MD, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; Geno J. Merli, MD, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania; Gerald P. Miletello, MD, Hematology/Oncology Clinic, Baton Rouge, Louisiana; Hyman B. Muss, MD, Medical Center Hospital of Vermont, Burlington, Vermont; Ellis J. Neufeld, MD, PhD, Children's Hospital, Boston, Massachusetts; Michael L. Nieder, MD, Rainbow Babies and Children's Hospital, Cleveland, Ohio; Timothy J. O'Rourke, MD, Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan; Donald J. Ponec, MD, Tri-City Medical Center Radiology Department, Oceanside, California; Dennis A. Priebe, MD, Washington Hospital Center, Washington, DC; Kanti R. Rai, MBBS, North Shore–Long Island Jewish Medical Center, New Hyde Park, New York.

#### References

1. Lokich JJ, Both A, Benotti P. Complications and management of implanted

central venous catheters. *J Clin Oncol* 1985; 3:710–717.

2. Tolar B, Gould JR. The timing and sequence of multiple device-related complications in patients with long term indwelling Groshong catheters. *Cancer* 1996; 78:1308–1313.
3. Hurtubise MR, Bottino JC, Lawson M, McCredie KB. Restoring patency of occluded central venous catheters. *Arch Surg* 1980; 115:212–213.
4. Haire WD, Lieberman RP, Lund GB, Edney J, Wiczorek BM. Obstructed central venous catheters—restoring function with a 12-hour infusion of low-dose urokinase. *Cancer* 1990; 66:2279–2285.
5. Haire WD, Atkinson JB, Stephens LC, Kotulak GD. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. *Thromb Haemost* 1994; 72:543–547.
6. Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusions? *J Parenteral Enteral Nutr* 1995; 19:75–79.
7. Atkinson JB, Bagnall HA, Gomperts E. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. *JPEN* 1990; 14:310–311.
8. Choi M, Masicotte MP, Marzinotto V, Chan AKC, Andrew M. Use of tissue plasminogen activator to clear blocked central venous lines in pediatric patients: a prospective cohort study [abstract]. *Blood* 1999; 94(suppl 1)25a.
9. Davis SN, Vermeulen L, Banton J, Schwartz BS, Williams EC. Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices. *Am J Health Syst Pharm* 2000; 57:1039–1045.
10. Isaac BF. Efficacy of cryopreserved alteplase for declotting thrombosed central catheters. *Ann Pharmacother* 2000; 34:533–534.
11. Hannah A, Buttimore AL. Thrombolysis of blocked hemodialysis catheter using recombinant tissue-type plasminogen activator. *Nephron* 1991; 59:517–518.
12. Paulsen D, Riesoeher A, Aasen M, Fauchald P. Use of tissue plasminogen activator for reopening of clotted dialysis catheters. *Nephron* 1993; 64:468–470.
13. Schenk P, Rosenkranz AR, Wolf G, Horl W, Traindl O. Recombinant tissue plasminogen activator is a useful alternative to heparin in priming Quinton Permcath. *Am J Kidney Dis* 2000; 35:130–136.
14. Daeihagn P, Jordan J, Chen J, Rocco M. Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. *Am J Kidney Dis* 2000; 36:75–79.

**Cathflo® Activase®  
(Alteplase)**

Powder for reconstitution for use in central venous access devices

**DESCRIPTION**

Cathflo® Activase® (Alteplase) is a tissue plasminogen activator (t-PA) produced by recombinant DNA technology. It is a sterile, purified glycoprotein of 527 amino acids. It is synthesized using the complementary DNA (cDNA) for natural human tissue-type plasminogen activator (t-PA) obtained from an established human cell line. The manufacturing process involves secretion of the enzyme Alteplase into the culture medium by an established mammalian cell line (Chinese hamster ovary cells) into which the cDNA for Alteplase has been genetically inserted.

Cathflo Activase (Alteplase) for injection is a sterile, white to pale yellow, lyophilized powder for intracatheter instillation for restoration of function to central venous access devices following reconstitution with Sterile Water for Injection, USP.

Each vial of Cathflo Activase contains 2.2 mg of Alteplase (which includes a 10% overfill), 77 mg of L-arginine, 0.2 mg of polysorbate 80, and phosphoric acid for pH adjustment. Each reconstituted vial will deliver 2 mg of Cathflo Activase, at a pH of approximately 7.3.

**CLINICAL PHARMACOLOGY**

Alteplase is an enzyme (serine protease) that has the property of fibrin-enhanced conversion of plasminogen to plasmin. It produces limited conversion of plasminogen in the absence of fibrin. Alteplase

binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin, thereby initiating local fibrinolysis (1).

In patients with acute myocardial infarction administered 100 mg of Activase as an accelerated intravenous infusion over 90 minutes, plasma clearance occurred with an initial half-life of less than 5 minutes and a terminal half-life of 72 minutes. Clearance is mediated primarily by the liver (2).

When Cathflo Activase is administered for restoration of function to central venous access devices according to the instructions in DOSAGE AND ADMINISTRATION, circulating plasma levels of Alteplase are not expected to reach pharmacologic concentrations. If a 2 mg dose of Alteplase were administered by bolus injection directly into the systemic circulation (rather than instilled into the catheter), the concentration of circulating Alteplase would be expected to return to endogenous circulating levels of 5–10 ng/mL within 30 minutes (1).

## **CLINICAL STUDIES**

Three clinical studies were performed in patients with improperly functioning central venous access devices (CVADs).

A placebo-controlled, double-blind, randomized trial (Trial 1) and a larger open-label trial (Trial 2) investigated the use of Alteplase in predominately adult patients who had an indwelling CVAD for administration of chemotherapy, total parenteral nutrition, or long-term administration of antibiotics or other medications. Both studies enrolled patients whose catheters were not functioning (defined as the inability to withdraw at least 3 mL of blood from the device) but had the ability to instill the necessary volume of study drug. Patients with hemodialysis catheters or a known

mechanical occlusion were excluded from both studies. Also excluded were patients considered at high risk for bleeding or embolization (see PRECAUTIONS, Bleeding), as well as patients who were younger than 2 years old or weighed less than 10 kg. Restoration of function was assessed by successful withdrawal of 3 mL of blood and infusion of 5 mL of saline through the catheter.

Trial 1 tested the efficacy of a 2 mg/2 mL Alteplase dose in restoring function to occluded catheters in 150 patients with catheter occlusion up to 24 hours in duration. Patients were randomized to receive either Alteplase or placebo instilled into the lumen of the catheter, and catheter function was assessed at 120 minutes. Restoration of function was assessed by successful withdrawal of 3 mL of blood and infusion of 5 mL of saline through the catheter. All patients whose catheters did not meet these criteria were then administered Alteplase, until function was restored or each patient had received up to two active doses. After the initial dose of study agent, 51 (67%) of 76 patients randomized to Alteplase and 12 (16%) of 74 patients randomized to placebo had catheter function restored. This resulted in a treatment-associated difference of 51% (95% CI is 37% to 64%). A total of 112 (88%) of 127 Alteplase-treated patients had restored function after up to two doses.

Trial 2 was an open-label, single arm trial in 995 patients with catheter dysfunction and included patients with occlusions present for any duration. Patients were treated with Alteplase with up to two doses of 2 mg/2 mL (less for children who weighed less than 30 kg, see DOSAGE AND ADMINISTRATION) instilled into the lumen of the catheter. Assessment for restoration of function was made at 30 minutes after each instillation. If function was not restored, catheter function was re-assessed

at 120 minutes. Thirty minutes after instillation of the first dose, 516 (52%) of 995 patients had restored catheter function. One hundred twenty minutes after the instillation of the first dose, 747 (75%) of 995 patients had restored catheter function. If function was not restored after the first dose, a second dose was administered. Two hundred nine patients received a second dose. Thirty minutes after instillation of the second dose, 70 (33%) of 209 patients had restored catheter function. One hundred twenty minutes after the instillation of the second dose, 97 (46%) of 209 patients had restored catheter function. A total of 844 (85%) of 995 patients had function restored after up to 2 doses.

Across Trials 1 and 2, 796 (68%) of 1043 patients with occlusions present for less than 14 days had restored function after one dose, and 902 (88%) had function restored after up to two doses. Of 53 patients with occlusions present for longer than 14 days, 30 (57%) patients had function restored after a single dose, and a total of 38 patients (72%) had restored function after up to two doses.

Three hundred forty-six patients who had successful treatment outcome were evaluated at 30 days after treatment. The incidence of recurrent catheter dysfunction within this period was 26%.

Trial 3 was an open-label, single-arm trial in 310 patients between the ages of 2 weeks and 17 years. All patients had catheter dysfunction defined as the inability to withdraw blood (at least 3 mL for patients  $\geq$  10 kg or at least 1 mL for patients  $<$  10 kg). Catheter dysfunction could be present for any duration. The indwelling CVADs (single-, double-, and triple-lumen, and implanted ports) were used for administration of chemotherapy, blood products or fluid replacement, total parenteral

nutrition, antibiotics, or other medications. Patients with hemodialysis catheters or known mechanical occlusions were excluded from the study, as were patients considered at high risk for bleeding or embolization. Patients were treated with up to two doses of Cathflo Activase instilled into the catheter lumen. For patients weighing  $\geq 30$  kg, the dose was 2 mg in 2 mL. For patients weighing  $< 30$  kg, the dose was 110% of the estimated internal lumen volume, not to exceed 2 mg in 2 mL. Restoration of function was assessed at 30 and 120 minutes (if required) after administration of each dose. Restoration of function was defined as the ability to withdraw fluid (3 mL in patients  $\geq 10$  kg; 1 mL in patients  $< 10$  kg) and infuse saline (5 mL in patients  $\geq 10$  kg; 3 mL in patients  $< 10$  kg).

The overall rate of catheter function restoration of 83% (257 of 310) was similar to that observed in Trial 2, as were the rates of function restoration at the intermediate assessments.

The three trials had similar rates of catheter function restoration among the catheter types studied (single-, double-, and triple-lumen, and implanted ports). No gender differences were observed in the rate of catheter function restoration. Results were similar across all age subgroups.

## **INDICATIONS AND USAGE**

Cathflo<sup>®</sup> Activase<sup>®</sup> (Alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.

## **CONTRAINDICATIONS**

Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation (see DESCRIPTION).

## **WARNINGS**

None.

## **PRECAUTIONS**

### **General**

Catheter dysfunction may be caused by a variety of conditions other than thrombus formation, such as catheter malposition, mechanical failure, constriction by a suture, and lipid deposits or drug precipitates within the catheter lumen. These types of conditions should be considered before treatment with Cathflo Activase.

Because of the risk of damage to the vascular wall or collapse of soft-walled catheters, vigorous suction should not be applied during attempts to determine catheter occlusion.

Excessive pressure should be avoided when Cathflo Activase is instilled into the catheter. Such force could cause rupture of the catheter or expulsion of the clot into the circulation.

### **Bleeding**

The most frequent adverse reaction associated with all thrombolytics in all approved indications is bleeding (3,4). Cathflo Activase has not been studied in patients known to be at risk for bleeding events that may be associated with the use of thrombolytics. Caution should be exercised with patients who have active internal bleeding or who have had any of the following within 48 hours: surgery, obstetrical delivery, percutaneous

biopsy of viscera or deep tissues, or puncture of non-compressible vessels. In addition, caution should be exercised with patients who have thrombocytopenia, other hemostatic defects (including those secondary to severe hepatic or renal disease), or any condition for which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location, or who are at high risk for embolic complications (e.g., venous thrombosis in the region of the catheter). Death and permanent disability have been reported in patients who have experienced stroke and other serious bleeding episodes when receiving pharmacologic doses of a thrombolytic.

Should serious bleeding in a critical location (e.g., intracranial, gastrointestinal, retroperitoneal, pericardial) occur, treatment with Cathflo Activase should be stopped and the drug should be withdrawn from the catheter.

### **Infections**

Cathflo Activase should be used with caution in the presence of known or suspected infection in the catheter. Using Cathflo Activase in patients with infected catheters may release a localized infection into the systemic circulation (see ADVERSE REACTIONS). As with all catheterization procedures, care should be used to maintain aseptic technique.

### **Hypersensitivity**

Hypersensitivity, including urticaria, angioedema and anaphylaxis, has been reported in association with use of Cathflo Activase. Monitor patients treated with Cathflo Activase for signs of hypersensitivity and treat appropriately if necessary.

### **Re-Administration**

In clinical trials, patients received up to two 2 mg/2 mL doses (4 mg total) of Alteplase. Additional re-administration of Cathflo Activase has not been studied. Antibody formation in patients receiving one or more doses of Cathflo Activase for restoration of function to CVADs has not been studied.

### **Drug Interactions**

The interaction of Cathflo Activase with other drugs has not been formally studied. Concomitant use of drugs affecting coagulation and/or platelet function has not been studied.

### **Drug/Laboratory Test Interactions**

Potential interactions between Cathflo Activase and laboratory tests have not been studied.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long-term studies in animals have not been performed to evaluate the carcinogenic potential or the effect on fertility. Short-term studies that evaluated tumorigenicity of Alteplase and effect on tumor metastases were negative in rodents. Studies to determine mutagenicity (Ames test) and chromosomal aberration assays in human lymphocytes were negative at all concentrations tested. Cytotoxicity, as reflected by a decrease in mitotic index, was evidenced only after prolonged exposure at high concentrations exceeding those expected to be achieved with Cathflo Activase.

### **Pregnancy**

Alteplase has been shown to have an embryocidal effect due to an increased postimplantation loss rate in rabbits when administered intravenously during organogenesis at a dose (3 mg/kg) approximately 50

times human exposure (based on AUC) at the dose for restoration of function to occluded CVADs. No maternal or fetal toxicity was evident at a dose (1 mg/kg) approximately 16 times human exposure at the dose for restoration of function to occluded CVADs.

There are no adequate and well-controlled studies in pregnant women. Cathflo Activase should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### **Nursing Mothers**

It is not known whether Cathflo Activase is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cathflo Activase is administered to a nursing woman.

### **Pediatric Use**

A total of 432 subjects under age 17 have received Cathflo Activase in the three trials. Rates of serious adverse events were similar in the pediatric and adult patients, as were the rates of catheter function restoration.

### **Geriatric Use**

In 312 patients enrolled who were age 65 years and over, no incidents of intracranial hemorrhage (ICH), embolic events, or major bleeding events were observed. One hundred three of these patients were age 75 years and over, and 12 were age 85 years and over. The effect of Alteplase on common age-related comorbidities has not been studied. In general, caution should be used in geriatric patients with conditions known to increase the risk of bleeding (see PRECAUTIONS, Bleeding).

## **ADVERSE REACTIONS**

The following adverse reactions are discussed in greater detail in Section PRECAUTIONS of the label:

- Bleeding
- Hypersensitivity

In the clinical trials, the most serious adverse events reported after treatment were sepsis (see PRECAUTIONS, Infections), gastrointestinal bleeding, and venous thrombosis.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

### **Trials 1 and 2**

The data described for Trials 1 and 2 reflect exposure to Cathflo Activase in 1122 patients, of whom 880 received a single dose and 242 received two sequential doses of Cathflo Activase.

In the Cathflo Activase Trials 1 and 2, only limited, focused types of serious adverse events were recorded, including death, major hemorrhage, intracranial hemorrhage, pulmonary or arterial emboli, and other serious adverse events not thought to be attributed to underlying disease or concurrent illness. Major hemorrhage was defined as severe blood loss (> 5 mL/kg), blood loss requiring transfusion, or blood loss causing hypotension. Non-serious adverse events and serious events thought to be due to underlying disease or concurrent illness were not recorded. Patients were observed for serious adverse events until catheter function was deemed to be restored or for a maximum of 4 or 6 hours depending on study. For most patients the observation period was 30 minutes to 2 hours. Spontaneously reported deaths and serious adverse events that were not thought to be related to the patient's underlying disease were also recorded during the 30 days following treatment.

Four catheter-related sepsis events occurred from 15 minutes to 1 day after treatment with Alteplase, and a fifth sepsis event occurred on Day 3 after Alteplase treatment. All 5 patients had positive catheter or peripheral blood cultures within 24 hours after symptom onset.

Three patients had a major hemorrhage from a gastrointestinal source from 2 to 3 days after Alteplase treatment. One case of injection site hemorrhage was observed at 4 hours after treatment in a patient with pre-existing thrombocytopenia. These events may have been related to underlying disease and treatments for malignancy, but a contribution to occurrence of the events from Alteplase cannot be ruled out. There were no reports of intracranial hemorrhage.

Three cases of subclavian and upper extremity deep venous thrombosis were reported 3 to 7 days after treatment. These events may have been related to underlying disease or to the long-term presence of an indwelling catheter, but a contribution to occurrence of the events from Alteplase treatment cannot be ruled out. There were no reports of pulmonary emboli.

There were no gender-related differences observed in the rates of adverse reactions. Adverse reactions profiles were similar across all age subgroups.

### **Trial 3**

In Trial 3 all serious adverse events were recorded with a specific interest in intracranial hemorrhage, major hemorrhage, thrombosis, embolic events, sepsis and catheter related complications. Major hemorrhage was defined as severe blood loss (> 5 mL/kg), blood loss requiring transfusion, or blood loss causing hypotension. Non-serious adverse events were not

recorded. Patients were observed until catheter function was deemed to be restored or for a maximum of 4 hours after the first dose. Additionally, serious adverse events were elicited from patients at 48 hours (up to 96 hours) following completion of treatment.

No pediatric patients in Trial 3 experienced an intracranial hemorrhage, major hemorrhage, thrombosis, or an embolic event.

Three cases of sepsis occurred 2 to 44 hours after treatment with Cathflo Activase. All of these patients had evidence of infection prior to administration of Cathflo Activase. An additional patient developed fever and lethargy within one day of Cathflo Activase administration, which required outpatient intravenous antibiotics. In one subject, the lumen of the catheter, placed 2 years previously, ruptured with infusion of the study drug.

There were no gender-related differences observed in the rates of adverse reactions. Adverse reactions profiles were similar across all age groups.

## **DOSAGE AND ADMINISTRATION**

Cathflo® Activase® (Alteplase) is for instillation into the dysfunctional catheter at a concentration of 1 mg/mL.

- Patients weighing  $\geq 30$  kg: 2 mg in 2 mL
- Patients weighing  $< 30$  kg: 110% of the internal lumen volume of the catheter, not to exceed 2 mg in 2 mL

If catheter function is not restored at 120 minutes after 1 dose of Cathflo Activase, a second dose may be instilled (see Instructions for Administration). There is no efficacy or safety information on dosing in excess of 2 mg per dose for this indication. Studies have not been

performed with administration of total doses greater than 4 mg (two 2-mg doses).

## **Instructions for Administration**

### *Preparation of Solution*

Reconstitute Cathflo Activase to a final concentration of 1 mg/mL:

1. Aseptically withdraw 2.2 mL of Sterile Water for Injection, USP (diluent is not provided). Do not use Bacteriostatic Water for Injection.
2. Inject the 2.2 mL of Sterile Water for Injection, USP, into the Cathflo Activase vial, directing the diluent stream into the powder. Slight foaming is not unusual; let the vial stand undisturbed to allow large bubbles to dissipate.
3. Mix by gently swirling until the contents are completely dissolved. Complete dissolution should occur within 3 minutes. **DO NOT SHAKE.** The reconstituted preparation results in a colorless to pale yellow transparent solution containing 1 mg/mL Cathflo Activase at a pH of approximately 7.3.
4. Cathflo Activase contains no antibacterial preservatives and should be reconstituted immediately before use. The solution may be used for intracatheter instillation within 8 hours following reconstitution when stored at 2–30°C (36–86°F).

**No other medication should be added to solutions containing Cathflo Activase.**

### *Instillation of Solution into the Catheter*

1. Inspect the product prior to administration for foreign matter and discoloration.
2. Withdraw 2 mL (2 mg) of solution from the reconstituted vial.
3. Instill the appropriate dose of Cathflo Activase (see DOSAGE AND ADMINISTRATION) into the occluded catheter.

4. After 30 minutes of dwell time, assess catheter function by attempting to aspirate blood. If the catheter is functional, go to Step 7. If the catheter is not functional, go to Step 5.
5. After 120 minutes of dwell time, assess catheter function by attempting to aspirate blood and catheter contents. If the catheter is functional, go to Step 7. If the catheter is not functional, go to Step 6.
6. If catheter function is not restored after one dose of Cathflo Activase, a second dose of equal amount may be instilled. Repeat the procedure beginning with Step 1 under Preparation of Solution.
7. If catheter function has been restored, aspirate 4–5 mL of blood in patients  $\geq 10$  kg or 3 mL in patients  $< 10$  kg to remove Cathflo Activase and residual clot, and gently irrigate the catheter with 0.9% Sodium Chloride Injection, USP.

**Any unused solution should be discarded.**

### **Stability and Storage**

Store lyophilized Cathflo Activase at refrigerated temperature (2–8°C/36–46°F). Do not use beyond the expiration date on the vial.

Protect the lyophilized material during extended storage from excessive exposure to light.

### **HOW SUPPLIED**

Cathflo Activase (Alteplase) for injection is supplied as a sterile, lyophilized powder in 2 mg vials.

Cathflo<sup>®</sup> Activase<sup>®</sup> is available in a carton that contains one 2 mg vial of Cathflo<sup>®</sup> Activase<sup>®</sup> (Alteplase): NDC 50242-041-64 or a carton that contains ten 2 mg vials of Cathflo<sup>®</sup> Activase<sup>®</sup> (Alteplase): NDC 50242-041-10.

## REFERENCES

1. Collen D, Lijnen HR. Fibrinolysis and the control of hemostasis. In: Stamatoyannopoulos G, Nienhui AW, Majerus PW, Varmus H, editors. The molecular basis of blood diseases, 2nd edition. Philadelphia: Saunders, 1994:662–88.
2. Tanswell P, Tebbe U, Neuhaus K-L, Glasle-Schwarz L, Wojick J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. *J Am Coll Cardiol* 1992;19:1071–5.
3. Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C, Sigmon KN, et al., and the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. *Am J Med* 1988;85:353–9.
4. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI), phase II trial. *Ann Int Med* 1991;115:256–65.

### **Cathflo® Activase® (Alteplase)**

Manufactured by:

**Genentech, Inc.**

A Member of the Roche Group

1 DNA Way

South San Francisco, CA

94080-4990

US License No. 1048

FDA Approval Date January 2005

Revised: 02/2019

Cathflo® Activase® is a trademark of

Genentech, Inc.

©2019 Genentech, Inc.